Gregory R. Friberg
Known title: EVP, Chief R&D OfficerCIK: 0002038768
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 4,086 | $245K | 9/30/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,281 | $177K | 5/7/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,629 | $91K | 3/17/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 19,150 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 6,326 | $382K | 2/26/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 3,304 | $179K | 9/30/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 17,750 | $0 | 3/17/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 21,190 | $0 | 9/30/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 7,870 | $0 | 9/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.